esophagitis/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 52 rezilta yo

Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for

The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials. OBJECTIVE To assess the long-term clinical safety of dose-titrated lansoprazole as maintenance therapy for up to 82 months in

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg) have similar efficacy and safety in the treatment of grade II-IV reflux oesophagitis (Savary-Miller classification). OBJECTIVE To compare the efficacy and safety of once-daily doses of pantoprazole

Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Gastro-oesophageal reflux disease (GORD) - reflux of stomach contents +/- bile into the oesophagus causing symptoms such as heartburn and acid reflux - is a common relapsing and remitting disease which often requires long-term maintenance therapy. Patients with GORD may have oesophagitis

WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The pharmacologic profile of the new proton pump inhibitor esomeprazole has demonstrated advantages over omeprazole that suggest clinical benefits for patients with acid-related disease. METHODS 1960 patients with endoscopy-confirmed reflux oesophagitis (RO) were randomized to once daily

Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the safety and tolerability of long term treatment with esomeprazole in patients with healed erosive oesophagitis, and to describe its efficacy in the maintenance of healing. METHODS US multicentre, noncomparative, nonblind study. METHODS 807 patients with endoscopically

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND In numerous clinical trials, proton pump inhibitors have demonstrated potent acid suppression and healing of erosive oesophagitis, as well as successful symptom relief for the entire spectrum of gastro-oesophageal reflux disease. OBJECTIVE The 'Future of Acid Suppression Therapy' (FAST)

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Lansoprazole, a substituted benzimidazole, is a proton pump inhibitor which is highly effective in the control of 24-h intragastric acidity. The aim of this multicentre, randomized, double-blind study was to compare lansoprazole 30 mg once daily and omeprazole 20 mg once daily in the

Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND In gastroesophageal reflux disease (GERD), the frequency of heartburn symptoms and erosive esophagitis (EE) increases with age in children and adolescents. Proton pump inhibitor, dexlansoprazole, is approved for healing EE of all grades, maintenance of healed EE, relief of heartburn, and

Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with reflux esophagitis (grade II or III, Savary-Miller, intention-to-treat, n=256, age range 19-82 years) were randomly assigned to a double-blind, double-dummy treatment with either pantoprazole 40 mg once daily or ranitidine 150 mg twice daily. After 4 weeks, each patient was clinically

Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The aim of this study was to assess the efficacy and safety of esomeprazole 40 mg once daily (q.d.) in healing reflux oesophagitis at 4 and 8 weeks, and the efficacy of esomeprazole 20 mg q.d. for 12 weeks in the maintenance of remission. METHODS A total of 235 patients with

Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND It has been speculated that intake of nonsteroidal anti-inflammatory drugs (NSAIDs) represents a risk factor for the occurrence of esophagitis and esophageal strictures. METHODS A case-control study was conducted to compare the occurrence of comorbid diseases treated with NSAIDs in case

Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Eosinophilic esophagitis is a chronic allergic disease with insufficient treatment options. Results from animal studies suggest that IL-5 induces eosinophil trafficking in the esophagus. OBJECTIVE We sought to evaluate the effect of reslizumab, a neutralizing antibody against IL-5, in

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE In patients with gastroesophageal reflux disease (GERD), esomeprazole, the S-isomer of omeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the racemic parent compound. This study was designed to further evaluate the efficacy and tolerability of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye